{"entity":{"id":"nct07739966","kind":"trial","name":"A Study of DS-3939a in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of pembrolizumab, carboplatin and pemetrexed in lung cancer, run by Daiichi Sankyo, not yet recruiting.","summary":"A Study of DS-3939a in Participants With Solid Tumors is a phase 1/2, interventional study registered as NCT07739966 by Daiichi Sankyo, with a registry enrolment figure of 400 participants, started 2026-10-01 and due to reach its primary completion in 2030-07-31. Interventions recorded: DS-3939a; Pembrolizumab; Carboplatin; Pemetrexed; DS-1103a. Conditions listed: Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer. Primary outcome: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs); Part 1: Number of Participants With TEAEs; Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by Investigator. Lung eligibility wording from the registry: \"Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07739966","url":"https://clinicaltrials.gov/study/NCT07739966"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["pembrolizumab","carboplatin","pemetrexed"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07739966","phase":"1/2","setting":"A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors","sponsor":"Daiichi Sankyo","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07739966/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}